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economic burden, is particularly problematic in asthma and
chronic obstructive pulmonary disease management because of
heterogeneous patient populations and the need for an inhaled
route of drug administration. Symptom variability,
comorbidities, and device switching further add to suboptimal
adherence rates. As opposed to controlled clinical trials, real-life
studies show consistently low inhaler adherence in daily practice,
yet exact adherence rates have long been affected by
disagreement on standardized definitions. The recently
developed Ascertaining Barriers to Compliance taxonomy helps
to address adherence research disparities by identifying 3 phases
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Nonadherence to inhaled treatment regimens for asthma and
chronic obstructive pulmonary disease (COPD) is well known as
being endemic and a central issue in the quality and economics of
ambulatory medical care and drug trials. Nonadherence for these
conditions is reported to be higher than that formany other chronic
diseases (70%-80% vs 50%, respectively).1,2 Indeed, adherence is
lower for asthma inhaler treatments than for antihypertensives,
diabetes treatments, statins, proton pump inhibitors, and breast
cancer treatments (Figure 1).3
The lack of an agreed definition for adherence has previously
hindered research into this important area, with few studies
examining the epidemiology, causes, and consequences of poor
adherence using standardized terminology. Adherence and
compliance are often used interchangeably, but they are not
exactly the same. The term noncompliance has paternalistic as-
sociations, suggesting a possibly deliberate lack of patient
involvement in their medication, whereas nonadherence is less
judgmental and is therefore generally the preferred term.4
The newly established Ascertaining Barriers to Compliance
taxonomy was developed to address the standardization of
terminology, helping to facilitate meaningful clinical discussion
and aid research analysis. Asthma and COPD are chronic diseases
that will particularly benefit from this initiative because of the
additional challenges presented by inhaler technique and the dif-
ference in patient profiles between the 2 conditions that are likely
to affect adherence behaviors (eg, age of onset, prognosis, etc).1
J ALLERGY CLIN IMMUNOL PRACT
MONTH 2017
2 DEKHUIJZEN ETAL100
90
Oncology-breast
DiabetesAbbreviations used
Cardiovascular-hypertensionCOPD- chronic obstructive pulmonary disease80 Cardiovascular-statin
DPI- dry-powder inhalerGastrointestinal-PPI70)pMDI- pressurized metered-dose inhalerRespiratory-asthma inhaled CS
Respiratory-asthma bronchodilator
Time (months)
60
50
40
30
20
10
0
1 22
A
dh
er
en
ce
 (%
21201918171615141312111098765432
FIGURE 1. Adherence in chronic diseases. Patient adherence over
time for various drug products (source of data: NDC Health). CS,
Corticosteroid; PPI, proton pump inhibitor. Reprinted from Smith
et al3 (Copyright 2010), with permission from Mary Ann Liebert,
Inc. (permission conveyed through Copyright Clearance Center,
Inc).
FIGURE 2. Multiple causes of nonadherence. Patient adherence to
medication is influenced by a number of factors relating to how
the individual judges the necessity of their treatment relative to
their concerns. Reprinted from Horne12 (Copyright 2006), with
permission from Elsevier.The Ascertaining Barriers to Compliance taxonomy identifies
3 phases of adherence. The first is initiation, which describes
when a patient takes the first dose of their medication. This
is followed by implementation, which relates to how well a pa-
tient’s dosing behavior corresponds to the prescribed regimen
from the first dose to the last dose, with inhaler technique of
prime importance. The final phase is discontinuation, which
marks the end of therapy, and is integral to the level of persis-
tence, or time to discontinuation.5 In clinical practice, there may
be more than 1 sequence of these phases because of reinitiation
of treatment.
Assessment of adherence is complex. Adherence to inhaled
treatment regimens is generally greater in classical randomized
controlled trials than in real-world studies.6-8 The levels of
adherence and inhaler technique competence seen in clinical trials
are no doubt influenced by trial conditions (eg, restrictive inclu-
sion criteria, short duration, health care professional support, etc)
and close monitoring, which may fail to reflect real-world differ-
ences between devices. Conversely, the methodology of real-world
studies means that poor disease control may be related to factors
other than the inhalation device, which are not easily differentiated
(eg, inclusion of smokers and patients with certain comorbid
conditions who are generally excluded from clinical trials).6,9,10
Furthermore, observational studies rarely report initiation or
persistence data, concentrating instead on implementation.5 This
has serious implications for adherence research because up to 25%
of patients fail to collect their first prescription.5 Differentiating
between true discontinuation and possible suboptimal imple-
mentation is key to understanding nonadherence.5
Despite the advances in respiratory care that have been
introduced over the last 50 years, suboptimal control still ac-
counts for a large proportion of the costs incurred by asthma and
COPD. It is therefore time to address the underlying problem of
nonadherence and make better use of available resources.11
In this review, we aim to provide an overview of the causes
and consequences of nonadherence, discuss successful adherence-
enhancing interventions, and provide a set of recommendations
to ultimately improve asthma and COPD control and lower
related health care spending.
CAUSES AND EFFECTS OF SUBOPTIMAL
ADHERENCE
Adherence to inhaled therapies is worse than with oral and
injected therapies (asthma) and transdermal formulations
(COPD).4 This is at least partly due to the perceived complexity
of inhaler administration, as well as a possible lack of confidence
in this route of drug delivery.4
Causes
There are numerous causes of nonadherence with inhaler use,
which can be broadly broken down into intentional and unin-
tentional factors (Figure 2).12 Intentional factors include
ambivalence to (or lack of confidence in) treatment, denial of
diagnosis, embarrassment about using inhalers in socialsituations, peer-group pressures (particularly applicable to ado-
lescents), concern about adverse events, and erroneous beliefs
that treatment can be stopped because symptoms have
improved.4,13,14
Unintentional factors include poor inhaler technique (even
though the patient thinks he or she is using it correctly),
incorrect inhaler use, lack of understanding about when to use an
inhaler, forgetfulness, and language barriers.10,13 Other factors
that can lead to unintentional nonadherence are the need for
multiple devices and/or concomitant conditions requiring poly-
pharmacy as well as a disruptive lifestyle, for example, frequent
long-haul flights, shift work, and personal/family crises.4,14-16
An alternative 3-part classification of nonadherence was
devised by the World Health Organization,1 which distinguishes
TABLE I. Costs of poor inhalation technique for patients using
budesonide/formoterol Turbohaler and fluticasone/salmeterol
Accuhaler
Resource use
Costs (V, million)
Spain Sweden
United
Kingdom
Hospitalization 57.7 21.5 11.5
Emergency department visits 3.6 4.2 1.2
Antimicrobial courses 0.2 0.1 2.4
Oral corticosteroids 0.7 0.2 2.0
Productive days lost 93.0 194.3 389.6
Adapted from Lewis et al29 (Copyright BioMed Central).
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to sporadic forgetfulness (eg, caused by a busy lifestyle); intelli-
gent nonadherence, which refers to intentional nonadherence as
a result of a reasoned decision to reject therapy as described
earlier; and unwitting nonadherence, which is a form of unin-
tentional nonadherence, usually due to misunderstanding in-
structions or poor inhaler technique.17
Additional considerations for patients with COPD that may
affect adherence include the fact that patients in this group are
generally older than those with asthma (asthma can be diagnosed
as early as 1 year of age vs a median age at diagnosis of 68 years
for COPD).18-20 Older age is accompanied by the potential for
lower cognitive function (up to 50% in some studies) and an
associated possibility of misunderstanding treatment details, plus
a greater probability of comorbidity/polypharmacy and the link
to unintentional nonadherence.14 Poorer prognosis in such pa-
tients and greater risk of disease-associated depression may both
contribute to adherence issues due to fatalism or apathy, while
mobility and dexterity problems also play a part. In addition,
patients with COPD often have limited ability to inhale with
enough force to achieve adequate drug delivery from a dry-
powder inhaler (DPI).20
Several studies have explored the impact of suboptimal treat-
ment on patient outcomes and health care resources including
drug costs, hospitalizations, and loss of productivity.
Effects: Clinical consequences
A number of studies have consistently demonstrated subop-
timal inhaler technique to be associated with poor clinical
outcomes.
A United Kingdom (UK) retrospective analysis investigated
the effect of poor pressurized metered-dose inhaler (pMDI)
technique on outcomes in 3981 patients with asthma in 15
general practices during 2009.21 Patients with poor pMDI
technique had higher risks of poor asthma control, as defined by
the Global Initiative for Asthma strategy guidelines,22 and
needed more systemic corticosteroid prescriptions than did those
who operated their device correctly. Of the patients who had
their inhaler technique tested using the asthma inhalation
monitor machine, 58%, 52%, and 38% failed to use the pMDI
correctly during the first, second, and third tests, respectively.
Incorrect inhaler use was significantly correlated with poor out-
comes. Compared with patients using their inhaler correctly,
almost 4 times as many patients failing the asthma inhalation
monitor test had uncontrolled asthma and more than twice asmany had partly controlled asthma (P < .0001 vs those who
passed the first test for both levels of control). In addition, 68%
of patients with 1 or more asthma exacerbations failed their first
inhaler technique test (P ¼ .03), while 67% of those prescribed a
short course of prednisolone in the previous 3 months also failed
their initial test (P < .05 vs those who passed their first test).21
In a retrospective US study based on data from the
SAPPHIRE (Study of Asthma Phenotypes and Pharmacoge-
nomic Interactions by Race-Ethnicity) trial,23 the relationship
between low levels of adherence to inhaled corticosteroids and
the incidence of asthma exacerbations was investigated. The
authors conservatively estimated that 24% of asthma exacerba-
tions could have been avoided with greater adherence to inhaled
corticosteroids. They also suggested that although incremental
improvements in adherence may be associated with a decreased
risk of exacerbations, this relationship is nonlinear and that an
adherence threshold of 75% of the prescribed dose is required to
significantly reduce exacerbations (hazard ratio, 0.61; 95% CI,
0.41-0.90 vs adherence 25%).
In a cross-sectional, observational study in Italy, 1664
adolescent and adult patients (aged >14 years) with asthma or
COPD were surveyed about inhaler-handling competence.24
Critical errors in device handling were significantly associated
with increased risk of hospitalization (P ¼ .001), emergency
department visits (P < .001), use of antibiotics (P < .001), and
courses of oral corticosteroids (P < .05). Similarly, a real-life
assessment compared exacerbation rates in 2935 patients with
COPD using 6 commonly prescribed inhalers in France.25
Inhalation technique was accurate in less than 40% of patients,
irrespective of device. The rate of severe exacerbations over 3
months of treatment doubled in patients with at least 1 critical
inhalation error compared with those with no errors (3.3% vs
6.9%, respectively; P < .05).
A systematic review of 12 studies in patients with COPD
investigated the association between level of adherence and
clinical and economic outcomes.26 Most studies were retro-
spective database studies. Seven studies focused on the impact of
adherence on hospitalization, most of which showed either
increased admissions with poor adherence or decreased admis-
sions for patients who adhered to their prescribed treatment.
Effects: Economic consequences
In both asthma and COPD, poor clinical outcomes have been
shown to translate into increased direct and indirect costs.
The total cost of asthma currently comprises up to 2% of
health care budgets.1 Treatment costs are 3.5 times higher in
patients experiencing acute asthma exacerbations than in patients
not experiencing exacerbations.27 Similarly, in patients with
COPD, exacerbations are thought to be responsible for 35% to
45% of all health care costs related to the disease.28
Two studies in patients with asthma or COPD quantified the
economic cost of inhaler misuse: one of themwas conducted across
3 European countries (the United Kingdom, Spain, and
Sweden)29 and the other was based in the United States.30 The
European study used a burden-of-illness economic model to
measure the impact of inhaler misuse over 1 year in patients using
the 2 most commonly prescribed dry-powder devices—budeso-
nide/formoterol Turbohaler and fluticasone/salmeterol Accuhaler.
The total cost incurred (on the basis of 2015 prices), including
costs for hospitalizations, emergency department visits, antimi-
crobial courses, oral corticosteroid courses, and productive days
TABLE II. Examples of clinical and economic impact of adherence in asthma and COPD
Study Study details Outcomes
Asthma
Morton et al32
(UK STAAR study)
Use of EMD over 1 y in 77 children (aged 6-16 y)
with poorly controlled asthma 1:1
randomization, in which one group (A) had
alarms and 3-monthly reviews, and the control
group (B) had no alarms or reviews
Clinical
Asthma control (as measured by the ACQ score)
significantly improved in both groups
over 12 mo.
Adherence was significantly greater in group A
(70% vs 49% in group B; P  .001) over the
study period.
GP/ED visits, days off school because of asthma,
requirement for courses of oral steroids, and
hospital admissions were all lower in group A
than in group B, significantly so for steroids
(P ¼ .008) and admissions (5 times lower;
P < .001).
Economic
There would appear to be cost savings using this
approach despite outlay for EMD.
Price et al33
(United States)
Prospective, real-world, cross-sectional survey of
243 US adult patients with asthma (41% of
whom had poorly controlled asthma) and their
physicians; questionnaires included DSP, ACT,
EQ-5D-3L, JSEQ, and MMAS-8
Clinical
24% of patients showed high adherence, 37%
medium/moderate adherence, and 40% low
adherence.
Improvements in asthma control, quality of sleep,
overall health status, and frequency of
exacerbations were significantly associated
with greater patient device satisfaction
(P ¼ .002) and higher adherence (P ¼ .049).
Zafari et al34
(United States)
Markov model of asthma to simulate impact of full
adherence on asthma control, exacerbations,
health care costs, and QALYs over a 10-y
period in patients who had uncontrolled asthma
at the current level of adherence (status quo)
Clinical
Compared with the status quo, ensuring full
adherence reduced the number of weeks with
uncontrolled asthma by 31% and the rate of
exacerbations by 40%.
Economic
The status quo level of control was associated
with a cost of US $2,786 and 7.55 QALYs over
10 y compared with US $5,973 and 7.68
QALYs for full adherence, representing an
incremental cost-effectiveness ratio of
US $24,515/QALY gained (all costs were
adjusted to 2011 US $).
Taking loss of productivity into account, the
model showed that full adherence would be
cost-effective and associated with a significant
return on investment.
COPD
Belleudi et al2
(Italy)
Population-based cohort study in 12,124 patients
aged 45 y who were discharged after a COPD
exacerbation in 3 Italian regions; health
care-linked data sets (for hospitalization,
mortality, and drugs) were used to assess the
impact of adherence on 5-y survival
Clinical
After a mean follow-up of 2.4 y, the mortality rate
was lower in all treatment categories when
medication was taken regularly rather than
occasionally:
LABA/ICS: 8.2% vs 11.3% (280 preventable
deaths vs regular LABA/ICS use)
LABA: 9.7% vs 12.7% (39 and 90 preventable
deaths, respectively, vs regular LABA/ICS use)
Chrystyn et al35
(international)
Large, multinational, cross-sectional, real-world
survey of 1443 patients using the DSP
questionnaire to examine the relationship
between inhaler satisfaction, adherence, and
health status
Clinical
The higher the level of adherence, the lower the
number of total exacerbations and
hospitalizations due to exacerbations in the
previous 12 mo (P < .001 for both).
Higher adherence was also associated with better
quality of life and sleep patterns
(both P < .0001).
(continued)
J ALLERGY CLIN IMMUNOL PRACT
MONTH 2017
4 DEKHUIJZEN ETAL
TABLE II. (Continued)
Study Study details Outcomes
van Boven et al36
(The Netherlands)
Evaluation of the cost-effectiveness of
PHARMACOP, the 3-mo intervention based in
170 Belgian community pharmacies that
significantly improved adherence and inhaler
technique
Economic
The PHARMACOP intervention was associated
with a cost saving of V227/patient within 1 y
and a significant decrease in exacerbation-
related hospitalizations.
The initial increase in PHARMACOP-related
costs (V161/patient) was offset by savings of
V388/patient for exacerbation-related expenses.
All costs were expressed in 2013 V.
Toy et al37
(United States)
Retrospective study using a large administrative
claims database covering 8 million insured lives
over a 7-y period
Economic
Using a multivariate regression model, higher
adherence was found to be correlated with
reduced annual number of inpatient days,
inpatient visits, and ED visits.
On the basis of 1000 patients, a 5% increase in
adherence would lead to an average reduction
of 2.5% in inpatient visits.
This translates into an estimated cost decrease of
US $296,598 for inpatient visits and US $7,410
for ED visits. Taking into account a slight
increase in outpatient costs, the net annual
saving would be US $300,789.
All costs from the survey were adjusted to
2008 US $.
Vestbo et al38
(UK TORCH study)
Observational adherence study within TORCH, a
3-y, multicenter, randomized, double-blind,
parallel-group, placebo-controlled study.
TORCH compared salmeterol, fluticasone
propionate, a combination of these drugs, and
placebo in 6112 patients with moderate to
severe COPD
Clinical
A strong association was found between
adherence and mortality and risk of
hospitalization due to exacerbations.
In a multivariate Cox model, good adherence
(80% use of study medication) was associated
with a 60% decreased risk of death at any time
in the 3-y study period and a decreased rate of
severe exacerbations of 44% (both P ¼ .001),
independent of study treatment.
ACQ, Asthma Control Questionnaire; ACT, asthma control test; DSP, Adelphi Disease-Specific Programme; ED, emergency department; EMD, electronic monitoring device;
EQ-5D-3L, three-level EuroQol five-dimensional questionnaire; GP, general practitioner; ICS, inhaled corticosteroid; JSEQ, Jenkins Sleep Evaluation Questionnaire; LABA,
long-acting b2-agonist; MMAS-8, 8-item Morisky Medication Adherence Scale; PHARMACOP, PHARMAceutical Care for COPD; QALY, quality-adjusted life-year; STAAR,
STudy of Asthma Adherence Reminders; TORCH, Towards a Revolution in COPD Health.
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(Sweden) to V406.7 million (United Kingdom).29 A breakdown
of these data is presented in Table I. In the US study, an annual
expenditure on inhalers of US $25 billion was assumed; taking the
level of inhaler misuse to be 28% to 68%, an estimated US $7 to
$17 billion was being wasted each year.30
In the previously discussed systematic review in patients
with COPD, 3 studies assessed costs associated with hospital-
izations due to poor adherence.26 All reported increased
medication costs but decreased costs for inpatient care and
COPD-related treatment in patients who adhered to their
treatment regimen.THE IMPACT OF IMPROVING ADHERENCE: A
“TREATABLE TRAIT”
There is compelling study evidence showing the positive
impact that improved adherence has on clinical and economic
outcomes. In a 2015 systematic review of 23 studies, 4 good-
quality studies in adult patients with asthma showed that a
25% increase in adherence was associated with approximately a
10% reduction in severe exacerbations.31 This finding has beensubstantiated in a number of studies in asthma and COPD. A
summary of the findings from key studies is presented in
Table II.THE IMPORTANCE OF TAILORING THE INHALER
TO THE PATIENT
There are more than 200 drug-inhaler device combinations
(branded and generic) available,39 and choosing the right device
for the individual patient is crucial to ensuring correct technique
and improving the likelihood of good adherence to therapy.40
Devices vary widely with regard to technique, patient suit-
ability, and patient preference, which makes the role of the
prescriber in selecting the optimal device potentially fraught and
overwhelming. The situation can be further complicated by pa-
tients being switched between inhalers for therapeutic reasons,
health insurance policies, or prescribing practices. Bioequivalent
versions of inhaled formulations may be delivered using different
devices, thus causing confusion to the patient and the potential
for adherence problems, either intentional or unintentional.41
There is therefore a strong case for maintaining patients on
their initial device, as any switch-related savings may be offset by
TABLE III. Factors affecting choice of inhaler device
Device type
Sufficient inspiratory flow* Insufficient inspiratory flow
Good
coordination
Poor
coordination
Good
coordination
Poor
coordination
pMDI alone U ✗ U ✗
pMDI þ spacer U U U U
DPI U U ✗ ✗
BAI U U U U
Soft-mist inhaler U † U †
Nebulizer U U U U
BAI, Breath-actuated inhaler.
Adapted from Dekhuijzen et al.44
*Able to produce at least 30 L/min.
†May need some level of coordination.
TABLE IV. Matching adherence strategies to the type of non-
adherence as defined by the World Health Organization
Type of nonadherence Intervention
Erratic (unintentional
nonadherence due to sporadic
forgetfulness, eg, because of a
busy lifestyle)
Simplify and tailor regimen (eg,
align time[s] of intake with
other drugs that are used, if
possible)
Implement behavioral strategies
such as linking with daily
habits (eg, storing inhaler next
to toothbrush) and sending
reminders (eg, by smartphone)
Self-monitoring with support
from others (eg, family
members)
Intelligent (intentional
nonadherence as a result of a
reasoned decision to reject
therapy)
Patient education and counseling
(eg, discuss mechanism of
action and ways to minimize
risk for side effects)
Negotiate therapy/shared decision
making (eg, in choosing the
inhaler)
Motivational interviewing (eg,
enhance patients’ intrinsic
motivation by emphatic
consultations with open
questions and respect for
autonomy)
Link therapy with personal goals
(eg, reduction in number of
annual exacerbations)
Reimbursement of therapy (if
financial reason)
Unwitting (unintentional
nonadherence, usually due to
misunderstanding instructions
or poor inhaler technique)
Written or visual self-
management plans
Patient education in inhaler
technique by doctor, nurse, or
pharmacist (reinforced
periodically)
Change inhaler if persistent
misuse or inability to use
current inhaler
Audiovisual materials (eg,
smartphone apps)
Reproduced from Lareau and Yawn15 (Copyright 2010), with permission from Dove
Medical Press Ltd (permission conveyed through Copyright Clearance Center, Inc).
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comes.42 Any change in device that is deemed necessary must be
supported by thorough training in technique and comprehensive
patient education.10
It makes sense, therefore, to carefully explore a patient’s con-
cerns and capabilities before selecting the most appropriate device.
The patient’s physical and mental abilities are key factors when
deciding which device is most appropriate. Coordination compe-
tence is important for pMDIs and breath-actuated devices because
failure to actuate efficiently can lead to drug deposition in the
oropharynx rather than in the lungs.10 Inhaler technique declines
over time in most patients, so it is prudent to monitor technique
periodically and provide educational interventions as required.
This is especially pertinent for elderly patients in cognitive decline
because they may experience problems in remembering inhaler
technique, may have dexterity issues that compromise delivery,
and are likely to have comorbid conditions and receive multiple
therapies. Given that we have yet to see sustained improvements in
patients’ ability to use inhalers correctly,43 prescribing simple de-
vices and combined formulations when possible is desirable to
encourage good adherence from the outset.
An important physical aspect of inhaler use involves the
inspiratory flow level of the patient because this can exclude some
device options, as presented in Table III.44 Although DPIs
theoretically avoid coordination issues by being solely driven by
inspiratory flow, this benefit is overridden if the patient has
suboptimal capacity to activate drug delivery. A general rule is
that a pMDI is suited to a patient who tends to use slow, deep
inhalations, whereas an ideal candidate for a DPI is one who can
easily perform a rapid, deep, and prolonged inspiration.45
Patient satisfaction is vital to adherence because patients who
are confident in taking their medication are more likely to
persevere with treatment.33 Real-world studies in both COPD
and asthma have shown a significant correlation between device
satisfaction, adherence, and outcomes.35,46 A patient’s support
network is also crucial, particularly in the case of vulnerable
patients. Exploring a patient’s understanding of the efficacy and
tolerability of their medication may highlight the need for an in-
depth discussion before device selection to manage expectations
and optimize treatment satisfaction.
A real-world COPD study reported that the main inhaler
characteristics influencing satisfaction were as follows: having a
robust construction that would not break easily; being easy to hold
and carry; and having simple, easy-to-follow instructions.35 In areal-world asthma study, the patient’s level of satisfaction with
their device was associated with improvements in quality of life,
sleep, exacerbation frequency, and health care professional visits;
the 3 most important satisfaction-related features were the same as
in the COPD study.46 Although patient choice is central to health
care policy, it is important for health care professionals to offer only
those devices that are suitable for the patient’s capability.
Current asthma and COPD treatment guidelines lack clear
and specific guidance on the choice of inhalation device, perhaps
assuming that clinicians have all the information they need
about inhaler characteristics and operation.9,45 This situation
needs to be addressed, given the confusing array of available
devices and physician time constraints; clear direction is required
on how to select the most appropriate inhaler for individual
patients.
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IN CLINICAL PRACTICE
As discussed, nonadherence manifests itself in 3 patterns, all
requiring patient-tailored solutions, as presented in Table IV.15,47
The need for a coordinated approach to suboptimal adherence
has been addressed by the First European Congress on Adher-
ence to Therapy, resulting in a European charter.48 This charter
acknowledges adherence to treatment as a right for patients with
chronic disease and gives comprehensive advice on how to
improve adherence by targeting patients and their families/care-
givers, health care professionals, manufacturers, guideline crea-
tors, and research institutions.48
Several adherence-enhancing intervention strategies warrant
further attention, including stimulating patient empowerment,
education and training, and use of electronic monitoring and
devices. These strategies are discussed in more detail herein.
Patient empowerment
A multifactorial approach to addressing nonadherence has
proven effective, as demonstrated in a randomized controlled
trial over 12 months in 146 Spanish patients with COPD.49
Patients were randomized to either a control group or an inter-
vention group that received motivational interviews to explore
beliefs and attitudes plus written and audiovisual materials
covering disease information and training in inhaler technique.
At the end of the study, the intervention group achieved a 79.5%
adherence rate compared with 49% in the control group
(P ¼ .002).
As a consequence of successful outcomes such as this,
motivational interviewing is being increasingly used as a step-
wise tool to empower patients over time. This can help them
overcome apathy, ambivalence, and poor levels of motivation
that can perpetuate poor adherence to medication, frequent
exacerbations, and compromised quality of life. Note that this
strategy is deemed particularly helpful to tackle intentional
nonadherence.
A second study in 734 patients with COPD investigated the
effectiveness of the 3-month PHARMACOP (PHARMAceutical
Care for COPD) intervention in improving adherence in patients
registered with 170 community pharmacies in Belgium.50 One
group of patients received standard pharmacist care and a second
group received 2 one-to-one counseling sessions, the first at
initiation and the second at the 1-month follow-up visit. The
sessions were tailored to each patient and included education,
inhaler technique, and addressing behavioral issues. At 3 months,
inhalation technique had significantly improved in the inter-
vention group compared with the control group, with a mean
estimated difference of 13.5% in percentage of correct inhalation
steps (P < .0001). The intervention corrected almost all major
technique errors. Notably, the annual hospitalization rate was
significantly lower in the intervention group compared with the
control group (P ¼ .003).
Education and training
Most patients requiring inhaler therapy are managed at the
community level, which puts primary care health professionals in a
key position to reach the greatest number of patients with
adherence-improving initiatives. As can be seen from the
PHARMACOP study, pharmacist involvement in adherence stra-
tegies is very effective.50 Their accessibility, respect, and knowledge
make them ideally placed to counsel patients about their inhalertherapy at all stages of the adherence pathway—initiation (setting
expectations at first prescription), implementation (device training;
identifying over-/under-usage through drug records), and discon-
tinuation (using medicine-use reviews to assess persistence)—
although their exact role may vary by country and setting.51
Ensuring that health care professionals are familiar with
inhaler techniques is key to any such program and it is therefore
of concern that 39% to 85% of doctors, nurses, and respiratory
therapists have limited expertise in the proper use of marketed
devices.10,30,52,53 Practical training tools are available to help
health care professionals understand how to use an inhalation
device properly so they can pass on this knowledge to their pa-
tients. Even though this can be a challenge given the time con-
straints in general practice, the clinical and economic benefits are
potentially worth the commitment.9,32,34,36
An open, empathetic approach to consultations encourages
patients to be honest about their concerns and beliefs so that
these can be addressed before they become detrimental to disease
control.51 A well-established approach is to ask the patient to
repeat what they have understood from the consultation, thus
ensuring that the patient does not leave having misunderstood
important information.51 Tackling the subject of adherence with
a patient can be a sensitive subject because it is easy for patients
to inadvertently feel like they are being judged or reprimanded,
potentially making their answers unreliable. One suggestion is to
use neutral language to initiate discussion, such as “Lots of
people don’t take their inhalers as prescribed.”51 Also, asking
about day-to-day management at home and practicing nonverbal
attentiveness, such as head nodding and eye-to-eye contact, can
facilitate openness.51
An important finding in adherence studies is that adherence is
improved by sharing decision making with the patient.13,51,54
When the patient is involved in their own care, they feel
empowered and are more likely to learn about their condition,
understand the importance of taking their doses correctly, and
endeavor to do so. That said, this approach is more appropriate
for patients who are willing and able to participate, taking into
consideration age (younger rather than older patients), education
(more rather than less educated), and current level of adherence
(worse rather than better).51
Of course, the issue of cost-effectiveness is of prime impor-
tance in these times of severe budgetary restrictions. However,
focusing on subsets of patients most likely to benefit from
improved adherence has the potential to prove cost-effective
across both asthma and COPD. These subgroups are patients
of working age, those with polypharmacy, those with exacerba-
tions, and those with uncontrolled disease.51
In general, the adherence strategies on which to focus are
those that improve clinician-patient communication skills, use
adherence counseling, include adherence information feedback
(but of course only if it is viewed and acted on by the clinician),
or involve electronic dose monitoring.51
Use of electronic monitoring and digital technology
Electronic dose monitoring has been shown to have a positive
impact on adherence in both asthma and COPD and is rising in
popularity because of its precision and objectiveness.4,32,55 The
cost benefits of electronic monitoring remain unclear, but it has
the potential to improve asthma control through more efficient
disease management.56 The STAAR (STudy of Asthma Adher-
ence Reminders) study suggested a potential for savings despite
J ALLERGY CLIN IMMUNOL PRACT
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technology, the more rapidly product costs will decrease.17,32
The value of the objectiveness of electronic dose monitoring
has been shown in a prospective observational study. In this
study, 204 patients with COPD were discharged from hospital
with an electronic audio-recording device attached to their pre-
venter inhaler and then followed for 1 month.57 Data collected
included quantity and quality of inhaler use, (reason for) hospital
admissions, disease severity, and personal factors (eg, cognitive
function), allowing measurement of both intentional and unin-
tentional nonadherence. The adherence patterns identified hel-
ped inform clinicians as to which strategies would be likely to
improve adherence. The mean actual adherence rate (a combi-
nation of intentional and unintentional nonadherence) over the
study period was 22.9% of what would be expected if all doses
had been taken correctly; most patients made errors in both
inhaler use and technique.57
A second cross-sectional, multicenter study in 1009 patients
used the objectiveness of electronic monitoring to validate the
12-item Test of Adherence to Inhalers, a questionnaire used in
asthma and COPD. The group using electronic monitoring was
compared with the self-report group to allow validation of the
new tool to easily identify nonadherence in patients and help
classify barriers to effective inhaler use.58 Results showed that in
addition to adequate classification of adherence, the Test of
Adherence to Inhalers instrument determined the predominant
pattern of nonadherence in individual patients.58
Digital technology is also advancing rapidly in the field of
telehealth, where platforms such as text messaging, telephone-
based advisory services, follow-up/feedback via Internet, smart-
phone apps, and Bluetooth technology are becoming increasingly
sophisticated and make an important contribution to the tools
available to the clinician and patient.9,59,60Recommendations
Although the advances in respiratory medicine have theoreti-
cally improved outcomes for patients with asthma or COPD,
these will continue to be compromised by poor adherence. It has
been clearly shown in numerous clinical and real-world studies
that improving adherence ultimately improves clinical and eco-
nomic outcomes. It is therefore crucial to health care budgets and
patient well-being that such interventions are implemented to
address the issue of nonadherence.
The potential for objective monitoring has never been greater,
and unless payers incorporate such adherence strategies into their
asthma and COPD management policies, a key opportunity will
continue to be missed. Electronic monitoring is a valuable option
for the objective assessment of adherence and inhaler technique;
after the initial financial outlay, long-term savings can be ach-
ieved. Combining this with other educational approaches, such
as motivational interviewing and patient education, would be
effective in reducing the cost of respiratory care. This would of
course involve longer consultation times than currently allowed,
but again, the cost of this would be offset by improved control
and associated economic benefits.
Manufacturers can also play their part by incorporating elec-
tronic monitoring devices into their inhalers, which would mean
an initial price increase, but the laws of economy of scale would
eventually bring costs down and savings would rise. Manufac-
turers should also endeavor to make their inhalers as simple andintuitive to use as possible, ideally using visual or auditory signals
when the correct technique has been achieved.
Involving patients in their own treatment has been shown to have
a beneficial effect on adherence. This can be achieved using relatively
low-cost initiatives, including educational materials and the input of
community pharmacists—an often-underused resource.
CONCLUSIONS
Improving adherence—and hence improving clinical out-
comes and reducing costs—in asthma and COPD appears to be
eminently achievable with the implementation of appropriate
strategies.
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